Cord Blood Plus

Cord Blood Plus is a biotechnology company based in Galveston, Texas, focused on developing proprietary cord blood stem cell expansion technology. The company's primary mission is to produce granulocyte and monocyte progenitors from umbilical cord blood to improve outcomes for patients undergoing chemotherapy, specifically targeting breast cancer. By accelerating the recovery of the immune system, the therapy aims to prevent infections, shorten hospital stays, and reduce the overall burden of chemotherapy-induced complications. Cord Blood Plus has received Small Business Innovation Research (SBIR) funding from the National Institutes of Health (NIH) to advance its regulatory and clinical development toward Phase 1 trials.